By RadNet, Inc.
Publication Date: 2026-03-02 10:45:00
-
Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, thoracic, pulmonary and neurological medicine applications.
-
Gleamer’s leadership in routine imaging, and particularly x-rays, is unparalleled through the breadth and scope of its cloud-first AI solutions.
-
DeepHealth, combined with Gleamer’s solutions, will provide the industry’s most comprehensive portfolio of native clinical AI solutions and services across all major imaging modalities.
-
Gleamer generated Annual Recurring Revenue (“ARR”) I The compound annual growth rate is more than 90% from 2022 to 2025 and is expected to reach approximately $30 million ARR in 2026.
-
The acquisition expands DeepHealth’s global commercial sales team and adds a strong research and development team that…